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ABSTRACT
An abstract of the thesis of Darcie Babcock for the Master of Science in Biology

presented May 1, 1996.

Title: Mutation analysis offibrillin-2 (FBN2) and microfibril associated protein-3 (MFAP3): two genes associated with congenital contractural arachnodactyly (CCA), also known
as Beal's syndrome.

Congenital Contractural Arachnodactyly (CCA), also known as Beal's syndrome,
is an autosomal dominant disorder characterized by multiple congenital joint contractures,
arachnodactyly, dolichostenomelia, and scoliosis with only rare ocular or cardiovascular
involvement. CCA has been linked to the fibrillin-2 (FBN2) gene located on chromosome
5q23-31. The phenotype ofCCA is similar to Marfan syndrome (MFS) which is caused by
defects in the fibrillin-1 (FBNl) gene located on chromosome 15. Fibrillin-1 and fibrillin-2
are components of extracellular matrix (ECM) elastic microfibrils. The linkage studies
performed on families affected with CCA suggest that another gene in the area ofFBN2
could also be responsible for CCA. Microfibril associated protein-3 (MF AP-3), another
microfibril protein gene, has been localized to chromosome 5q32-33.2, the region of
FBN2.
This study involves mutation analysis of five patients affected with CCA, three of
whom are representative of families affected with CCA. Mutation analysis was
performed by chemical mismatch cleavage (CMC) analysis and nonisotopic RNase
cleavage assay (NIRCA) analysis on both FBN2 and MF AP-3 cDNA. Prior to this study

only two mutations in FBN2 have been reported in two isolated patients with CCA and
none have been reported for MFAP-3. The two mutations reported in FBN2 have not
been confirmed in other affected family members. Mutation analysis by CMC completed
in this study did not reveal any mutations in either FBN2 or MF AP-3. Reanalysis by
NIRCA revealed two mutations in FBN2. One mutation which results in the skipping of
exon 31 occurs in an intron and its location is presently unknown. The other mutation, a
G to C transversion at nucleotide 3340, predicting a histidine substitution for an
asparagine, is a mutation at the -1 position of the 5' splice site of an intron which results in
partial exon skipping although it is unknown whether exon 25 or 26 is skipped. The
missense mutation and partial exon skipping result in two different forms of mutant
fibrillin-2 molecules. Both of the mutations are present in patients with additional affected
family members. Characterization of these mutations will confirm the cosegregation of
FBN2 mutations with the CCA phenotype.

MUTATION ANALYSIS OF FIBRILLIN-2 (FBN2) AND MICROFIBRIL
ASSOCIATED PROTEIN-3 (MFAP-3): TWO GENES ASSOCIATED WITH
CONGENITAL CONTRACTURAL ARACHNODACTYL Y (CCA), ALSO KNOWN
AS BEAL'S SYNDROME.

by
DARCIE BABCOCK

A thesis submitted in partial fulfillment of the requirements for the degree of

MASTER OF SCIENCE

m
BIOLOGY

Portland State University
1996

ACKNOWLEDGMENTS

I would like most of all to thank my thesis advisor, Dr. Cheryl Maslen, without
whom this would truly have never been possible. Her limitless knowledge, support and
patience never went unnoticed.
I would also like to thank Dr. Robert Glanville, our esteemed collaborator at

Shriner' s Hospital for Crippled Children, and the other members of Cheryl's lab,
specifically Paul Rupp, for their help and moral support. Don't worry, Paul, this will
happen to you, too. I only hope that I will be as much help to you as you have been to
me.
Many thanks also to the members of my thesis committee who were essential in
making this collaborative effort not only a reality but also a great success.
Finally I would like to thank my family and dear friend Amy for their support and
faith in me, and also for fielding those panicked phone calls, assuring me that all of the
sacrifices I was making were indeed worth it.

TABLE OF CONTENTS
ACKNOWLEDGEMENTS

...............................................

:IN"TRODUCTION ••••••••••••••••••••••••••••••••••••••••••••••••••••••.•

v

1

...........................................

8

.....................................................

8

......................................................
RNA Isolation ......................................................

9

MATERIALS AND METHODS
Patient Samples
DNA Isolation

cDNA Sythesis ..................................................... .
Mutation Analysis

...................................................

CMC •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••
NIRCA •••••••••••••••••••••••••••••••••••••••••••••••••••••••••
Sequencing •••••••••••••••••••••••••••••••••••••••••••••••••••••••••

11

12
12

15
16

17

ASO Analysis
:RESULTS ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••
Mutation Analysis

10

...................................................

CMC ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••
NIRCA ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••

Sequencing ........................................................ .
ASO Analysis
DISCUSSION ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••
Mutation Analysis
CMC ••••••••••••••••••••••••••••••••••••••••••••••••.••••.••••.•
NIRCA ••••••••••••••••••••••••••••••••••••••••••••••••.••••.••••
Sequencing •••••••••••••••••••••••••••••••••••••••••••••••••••••••••

Conclusions ........................................................ .

19
19
19

20
21

22
24
24
24

26
27

29

APPENDIX I: ADDENUM

................................................

.APPE'NDIX II: FIGURES •••••••••••••••.•••••••••••••••••••••••••••••••••
Figure I: Fibrillin-2 Diagram

.........................................

Figure 2: NIRCA Diagram ••••.••••••••••••••••••.••••••••.••••••••••
Figure 3: CMC Analysis of Fibrillin-2 Polymorphism at Position
7197 •.••.•••••...••••••••.......•••••••.••••••••••••..•..
Figure 4: NIRCA Analysis ofFibrillin-2 Polymorphism at Position

31
36

37
38
39

40

7197 ...............•............•.....•..............•....

Figure 5: Sequencing ofFibrillin-2 Possible Mutations at Positions

41

486 and 487 •••••••••••••••.•••••••••••••••••••••••..•...••

Figure 6: Sequencing ofFibrillin-2 Polymorphism at Position

42

7197 ••••••••••••....••••••••••.......•.•.•..•.•...•••.••••

APPENDIX III: GENERAL ABBREVIATIONS AND SOLUTIONS
Abbreviations
Solutions .......................................................... .

.APPE'NDIX IV: TABLES •••••••••••••••....•••••••••••••.••••••.•••••••••
Table I: CMC Primers ••••••••••••••••••••••••••••••••••••••••••••••
Table 2: NIRCA Primers ••••••••••••••••••••••••••••••••••••••••••••
Table 3: Sequencing Primers •••••••.•••••••••.•••••••..••••••••••••••
Table 4: Primers for ASO Analysis

Table 5: ASO Probes
REFERENCES ••••••••••••••••••••••••••••••••••••••••••.••••••••••••.••••

43
44

45
47
48
49

51

52
53

54

Introduction
Congenital Contractural arachnodactyly (CCA), also known as Beals syndrome,
was first described as a disorder distinct from Marfan syndrome (MFS) in 1971 by Rodney
K. Beals and Frederick Hecht. CCA is an autosomal dominant disorder characterized by
multiple congenital joint contractures, arachnodactyly (long, thin fingers),
dolichostenomelia ( long, thin limbs), scoliosis, and abnormality of the external ears,
11

usually referred to as "crumpled ears (Beals and Hecht, 1971). The congenital joint
contractures present in CCA are at their maximum at birth and in some cases lessen as the
patient ages (Hecht and Beals, 1972). CCA has a phenotype similar to MFS, with many
cases ofMFS reported in the early literature actually thought now to be cases of CCA
including the first case reported by Marfan in 1896 (Hecht and Beals, 1972). However,
CCA lacks ocular problems and aortic root dilitation which are the more serious traits
associated with MFS. Because CCA lacks aortic root dilation, it is not a fatal disorder
and therefore is not associated with early fatalities as seen in Marfan syndrome.
MFS has been shown to result from a variety of defects in the fibrillin-1 (FBNl)
gene located on chromosome 15 (Maslen and Glanville, 1993). Linkage analysis has
shown a close association between CCA and the fibrillin-2 (FBN2) gene located on
chromosome 5 (Lee et al., 1991; Tsipouras et al., 1992). The cDNA for FBN2 was
sequenced in 1994 (Zhang et al., 1994). The coding region ofFBN2 is approximately 11
kb (kilo base pairs), slightly longer than that ofFBNl. FBNl and FBN2 have high
sequence homology which may explain the phenotypic relationship between MFS and
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CCA. Figure 1 is a diagrammatic representation of the amino acid sequence ofFBN2,
indicating the different domains of the gene. The proteins produced by FBNI and FBN2
are both present in elastin-associated extracellular matrix (ECM) microfibrils. The fibrillins
are high molecular weight, single polypeptide, non-collagenous glycoproteins which are
highly insoluble. The tissue distributions of fibrillin-1 and fibrillin-2 are similar, with some
distinct differences (Zhang et al., 1994). One notable difference is that fibrillin-2 is present
in higher amounts in ECM microfibrils that are rich in elastic fibers such as in the elastic
cartilage in the external ear. This would correspond to the ear malformations seen in CCA
but not seen in MFS. Other differences in tissue distribution suggest the fibrillins have
related but distinct functions (Lee et al., 1991). Linkage analysis and tissue distribution
have resulted in FBN2 becoming the focus of studies of CCA. To date there have been
only two mutations found in FBN2 in two isolated patients with CCA (Putnam et al.,
1995). No shared mutations have been found in families affected with CCA.
Consequently, an inheritance pattern demonstrating co segregation of the CCA phenotype
with a FBN2 mutation has yet to be presented.
Very few mutations have been found in either FBNl or FBN2 using a variety of
mutation detection techniques. FBNl and FBN2 have high G-C to A-T ratios and it has
been speculated that mutation analysis of the genes has been difficult due to their G-C rich
structures. Single stranded conformational polymorphism (SSCP) analysis has detected
only approximately 25% of the mutations in FBNl found in patients with :MFS and less
than 20% of the mutations in FBN2 found in patients with CCA. These poor results have
made it difficult to prove that FBN2 mutations cause CCA.
2

The LOD scores for linkage between CCA and F~N2 are 6.2 at both e = 0.000
and e = 0.001 (Tsipouras et al., 1992). LOD scores refer to a statistical calculation of the
probability that the gene responsible for certain phenotypic characteristics is linked to a
polymorphism that is being used as a genetic marker. The calculation is the log10 of the
ratio of the probability that the loci are linked, to the probability that they are not linked.
These scores suggest the possibility that a gene near FBN2 could also play a key role in
CCA. MF AP-3 (microfibril associated protein-3) is another microfibril protein whose
gene has been localized to chromosome 5q32-33.2, near the region ofFBN2 (Abrams et
al., 1995). MFAP-3 has no known homology with any other known proteins. The coding
region ofMFAP-3 is 1089 bp consisting of two exons with one intron. MFAP-3 is known
to localize to elastic microfibrils. Little else is known about the tissue distribution of
MF AP-3 to date as it has only been cloned and sequenced recently. Due to the close
proximity between FBN2 and MF AP-3 and the lack of mutations implicating FBN2 as the
cause of CCA, it is possible that MF AP-3 could be also be associated with CCA.
For this study I proposed mutation analysis of five patients affected with CCA,
three of whom be long to families affected with CCA. This study of CCA was unique in
that it was the first to include a family affected with CCA. Mutation analysis was
performed by chemical mismatch cleavage (CMC) analysis and nonisotopic RNase
cleavage assay (NIRCA) analysis on both FBN2 and MF AP-3. While CMC is becoming a
widely used mutation analysis system, its use has not been reported by others in the
analysis of either FBN2 or MF AP-3. NIRCA has not yet been used for mutation analysis
of any genes in a published study.
3

Chemical mismatch cleavage (CMC) is a heteroduplex mutation analysis method
that has been reported to have the ability to detect single base changes in large DNA
fragments (Cotton et al., 1988; Grompe et al., 1989; Forrest et al., 1991; Mathew, 1991;
Grompe, 1993). CMC has been found to be one of the most sensitive of all of the
mutation analysis methods designed so far with the possibility of detecting I 00% of point
mutations and small deletions or rearrangements. CMC is also the mutation detection
system that is the least constrained by size with the possibility of analysis of a 1. 7 kb
fragment at one time. The large size of fragment that can be analyzed by CMC makes it
ideal for the detection of small mutations such as point mutations in very large genes.
The principle behind CMC is that a radioactive wild-type DNA and nonradioactive mutant DNA are denatured and annealed together to form a heteroduplex.
This heteroduplex is chemically modified with one of two different chemicals at the sites
of base pair mismatches and then cleaved with piperidine at the site of the chemical
modification. The resulting product is electrophoresed and analyzed with identically
treated normal heteroduplexes to reveal the presence of a mutation and its location within
the sequence to within 30 bp. Heteroduplexes are modified with osmium tetroxide for
mismatched thymines and hydroxylamine for mismatched cytosines. By using separately
radiolabeled sense and anti-sense strands, all mismatch combinations can be located. The
exact location of the mutation can therefore be found by direct sequencing of only a small
area of the gene. DNA-RNA heteroduplexes can also be analyzed. Non-radioactive
methods have been developed, but radioactivity is found to be more sensitive in the
detection of mutations versus false-positives, such as areas of compressions in the DNA.
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Compressions are areas where the DNA has formed secondary structures. These areas are
usually G-C rich areas. Besides the use of radioactivity, the chemical modifiers used for
CMC are highly toxic which is one of the drawbacks of this method.
NIRCA, or Nonisotopic RNase Cleavage Assay, is a mutation analysis method
based on RNase A cleavage assays ofRNA:DNA heteroduplexes (Myers et al., 1985) and
transcribed genes (Winter et al., 1985) that was developed by Ambion Inc. In these
assays, RNase A was found to cleave a single base pair mismatch in a radiolabeled RNA
probe that had been hybridized to a DNA target encompa·ssing a point mutation. The
resulting fragments were analyzed using a polyacrylamide gel. NIRCA is a modification of
this technique that detects mismatches between RNA:RNA hybrids by RNase cleavage
using wild-type and mutant RNA transcripts (Figure 2). PCR primers are generated which
have the T7 promoter sequence (5'-TAATACGACTCACTATAGGG-3') attached to the
sense or anti-sense primer and the SP6 promoter sequence(5'ATTTAGGTGACACTATAGGA-3') attached to the opposing primer. PCR products are
generated from cDNA using these primers. The RNA transcripts are then made by in

vitro transcription of the PCR products using either T7 or SP6 polymerase. Hybrids are
produced by combining wild-type and mutant sense and anti-sense RNA strands. The
hybrids are cleaved with RNase and the resulting fragments are run on an agarose gel. By
comparing the mutant samples with control samples, point mutations can be detected as
aberrant bands on the agarose gel. NIRCA, like CMC, can be used to analyze larger
fragments of DNA then other mutation analysis techniques with the optimal fragment size
for NIRCA being between 500 to 1000 bp. Also like CMC, NIRCA can localize the
5

mutation within the fragment analyzed, so once a mutation is found only a portion of the
fragment needs to be sequenced instead of the entire fragment. Unlike CMC, however,
NIRCA cannot predict the exact type of base pair mismatch, but as sequencing is
necessary for both methods to locate the exact position of the mutation, this is not a
detriment to the system. NIRCA has distinct advantages as a method of mutation analysis
because, unlike most of the other mutation detection systems, it doesn't require the use of
radioactive materials or toxic chemicals for analysis. NIRCA has also been found to be
faster and more sensitive when compared to other mutation detection systems when used
to detect known mutations. NIRCA has been tested in G-C and A-Urich targets and has
been found to be highly effective in detecting single base pair mutations.
Potential mutations located in either FBN2 or MFAP-3 were characterized by
sequencing PCR products generated for the area of the suspected mutation. Mutations
found by sequencing were confirmed in the patient and, if possible, in other family
members by ASO (allele specific oligonucleotide) analysis (Mathew, 1991; Maslen et al.,
1995). Normal controls were also screened to prove that the suspected mutations were
indeed mutations and not polymorphisms.
ASO analysis is a system of mutation detection that will confirm a single base pair
change. ASO analysis is useful to confirm single base pair changes when these changes do
not alter any restriction enzyme sites. ASO probes are radiolabeled oligonucleotides that
differ from the normal sequence by only one base pair corresponding to the mutation. A
pair of oligonucleotides are designed; one which perfectly matches the normal sequence
and one which perfectly matches the mutant sequence. ASO probes must be large enough
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to be unique within the target genome so they do not hybridize randomly. However,
random hybridization is not a major concern because PCR makes the target sequence very
specific. ASO probes must also be small enough to detect a single base change because
the hybridization of large probes to their target is not affected by small differences in
sequence or small changes in hybridization temperature but hybridization of small probes
to their target is easily disrupted by even a single base pair change or a change in the
temperature as small as a few degrees. ASO probes are therefore designed to be small,
between 11 bp and 20 bp in length, to insure their temperature dependent nature. PCR
product encompassing the suspected mutation is generated and bound to a nylon or
nitrocellulose membrane. The membrane is hybridizeded with one of the radiolabeled
ASO probes at a time. After hybridization, it is washed at a temperature specific to the
sequence of the probe. If the probe does not match the target sequence exactly
hybridization of the probe will be disrupted because the hybridization will not be
thermally stable. A positive signal will result if the mutati_on that matches the ASO is
present on either one or both of the patients alleles. If the suspected mutation is not
present, no signal will appear, which is interpreted as a negative signal. Therefore, an
ASO that matches the normal sequence can be used as a negative control when hybridized
to an allele with a sequence mutation. ASO probes can be used to confirm that a mutation
is homozygous or heterozygous, a virtue that was not necessary for this study as all
mutations were known to be heterozygous because CCA is an autosomal dominant
disorder. This, however, can be a factor in mutation analysis and confirmation in other
genes.

7

Materials and Methods

Patient Samples. Patient samples were provided as blood, tissue, or cultured fibroblast
samples through collaboration with Rod Beals, Beat Steinmann, and Uta Franke. RNA
and DNA samples from five patients affected with CCA were available for this study.
Three of these patients are from families affected with CCA. One family, denoted as
Family 1, patients 1-1-1, 1-11-1, and 1-11-2, is a well characterized CCA family that has
been followed for a number of years (Beals and Hecht, 1971). Patient 1-1-1 from this
family is the proband, the patient originally described with the disorder, and patients 1-11-1
and 1-11-2 are siblings and are patient 1-1-1 's offspring. Family 2, denoted as patients 2-11 and 2-1-2, are siblings. Family 3 consists of patient 3-1-1, the proband, patients 3-1-2
and 3-1-3, the proband's siblings, and patient 3-11-1, the offspring of patient 3-1-2. Patient
4-1-1 and 5-1-1 are the only patient from their respective families that were available. All

of these patients were characterized as being affected by several of the phenotypic
characteristics of CCA by persons qualified to make such a judgment before they were
received. Only the phenotypic characteristics of the patients from Family 1 were made
available. Blood samples were obtained using EDT A as ~n anticoagulant and were used
directly for DNA extraction. Tissue samples were cultured as fibroblast cell lines and
grown for RNA and DNA extraction by collaborators at Shriner' s Hospital. Control RNA
and DNA used were on hand in the laboratory or were isolated from samples of
individuals known to have no phenotypic characteristics of CCA.
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DNA Isolation. DNA was prepared from blood when possible using the white blood cell
nuclei (Bell et al., 1981) or from fibroblast cultures (Ausubel et al., 1995). DNA was
prepared from blood by centrifuging the blood at 900 x g for 15 minutes in a Beckman
table top centrifuge to separate the plasma from red and white blood cells. The white
blood cells were collected and mixed with BCL (blood cell lysis) buffer to lyse the white
blood cell membranes. The white blood cell nuclei were pelleted by centrifugation at 900
x g for 20 minutes in a Beckman table top centrifuge and the resuspended in NL (nuclear
lysis) buffer to digest the nuclear membranes. Proteinase K/SDS solution was added to
the digested white blood cell nuclei and the mixture was incubated at 37° C with shaking
for 12-24 hours. Proteinase K/SDS addition digests the proteins present in the cell. The
nucleic acids were extracted from the digested proteins using separate phenol and
chloroform/isoamyl alcohol (25: 1) extractions centrifuging after each extraction at 900 x g
for 10 minutes and were precipitated using 0.15M sodium acetate in 95% ethanol. The
DNA was pelleted by centrifuging at 2000 x g for 5 minutes in a Beckman table top
centrifuge, dried in a Savant Speed Vac, and resuspended in TE at 4° C overnight with
shaking. The DNA was reprecipitated by adding 7.SM ammonium acetate and 95%
ethanol. The DNA was pelleted by centrifuging at 2000 x g for 5 minutes in a Beckman
table top centrifuge and washed with 95% ethanol, repeating the centrifugation. The
DNA was dried in a Savant Speed Vac and resuspended in TE-4 at 4° C overnight with
shaking.. The concentration of DNA in solution was determined by UV
spectrophotometer. The DNA was stored at 4°C.
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DNA was isolated from cultured fibroblast cells by trypsinizing the adherent
fibroblast cells with IX Trypsin/EDT A, collecting the cells by centrifugation at 500 x g for
5 minutes in a Beckman table top centrifuge and washing the cells with PBS, repeating the
centrifugation. The cells were then mixed with digestion buffer and incubated overnight at
50°C, with shaking to digest the cellular membranes and proteins. The nucleic acids were
then extracted using a phenoVchloroform/isoamyl alcohol (25:24: I) extraction
centrifuging at 1400 x g for 10 minutes in a Beckman table top centrifuge. RNA was
digested by incubation at 37°C for I hour with a combination of30µg ofRNase A and
3µg ofRNase Tl and the phenoVchloroform/isoamyl alcohol extraction was repeated.
The DNA was precipitated using 7.SM ammonium acetate and 100% ethanol. The DNA
was pelleted by centrifuging at 1400 x g for 2 minutes in a Beckman table top centrifuge
and washed with 70% ethanol, repeating the centrifugation. The DNA was dried and
resuspended in TE-4 at 4°C overnight with gentle shaking. The concentration of the DNA
in solution was determined by UV spectrophotometer. The DNA was stored at 4°C.

RNA Isolation. RNA was prepared from cultured fibroblasts by cesium chloride gradient
separation (Ausubel et al., 1995). Adherent cultured fibroblast cells were trypsinyzed with

IX Trypsin/EDT A, collecting the cells by centrifugation at 500 x g for 5 minutes in a
Beckman table top centrifuge and washed with PBS, repeating the centrifugation. The
cells were then digested with GIT solution for 5 minutes at room temperature and passed
through an 18 gauge needle 10 times to shear the genomic DNA. The mixture was
layered over cesium chloride and centrifuged overnight in an ultra-centrifuge at 27,500
10

rpm. The cesium chloride was drained and the RNA pellet, located at the bottom of the
ultra-centrifuge tube, was resuspended in DEPC treated sterile, deionized water and
precipitated using 3M sodium acetate and 95% ethanol. The RNA was pelleted by
centrifuging at 14,000 rpm for 30 minutes in a micro-centrifuge. Residual cesium chloride
was removed by vortexing the pellet with 70% isopropanol/30% 0.2M sodium acetate and
spinning at 14,000 rpm for 10 minutes. The RNA was dried in a Savant Speed Vac and
resuspended in DEPC treated sterile, deionized water. The concentration of RNA in
solution was determined using a UV spectrophotometer. The RNA was stored at -80°C.

cDNA Synthesis. cDNA was synthesized from 20 µg of total RNA in a 20µ1 reaction
volume using random hexamers as a reverse transcription primer (Perkin Elmer Cetus) and
Super Script Reverse Transcriptase (BRL). The RNA was reduced to a volume of 1Oµl
by precipitation with 3M sodium acetate and 95% ethanol. The RNA was pelleted by
centrifuging at 14,000 rpm for 30 minutes in a micro-centrifuge and washed with 70%
ethanol, spinning at 14,000 rpm for 10 minutes. The RNA was dried in a Savant Speed
Vac and resuspended in DEPC treated sterile, deionized water, mixed with 50 llmol of
random hexamers, and heated to 70°C for I 0 minutes. The mixture was cooled quickly on
ice, 4µ1of5X reaction buffer (BRL), 2µ1 O. lM DTT, and lµl lOmM mixed dNTP stock
(Perkin Elmer Cetus) was added, and the mixture was heated to 37°C for 2 minutes. 40
Units of the RNase inhibitor RNasin (Promega) and 200 Units Super Script Reverse
Transcriptase were added and the mixture was incubated at 37°C for 1 hour. 1Oµg of
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RNase A was added to digest any residual RNA and the mixture was incubated at 37°C
for 30 minutes. The cDNA was stored at -80°C.

Mutation Analysis
Chemical Mismatch Cleavage. Mutation analysis was performed by chemical mismatch
cleavage, with some modifications as follows (Cotton et al., 1988; Grompe et al., 1989;
Mathew, 1991). First and second round PCR was performed using primers listed in Table
1 on normal and mutant cDNA synthesized from total RNA. Oligonucleotide primers
were designed using Oligo 5.0 Primer Analysis Software (National Bioscience, Inc.). PCR
was performed in a 100µ1 reaction volume using 2.5U Taq DNA polymerase (BRL), 10µ1
of lOX PCR buffer (BRL), 4µ1 50mM MgCh, 16µ1 lOmM mixed dNTP stock, and
lOOµM final concentration of PCR primers unless otherwise indicated. The thermal
profile for first round PCR was a two step PCR profile: 94 °C for 1 minutes, 68°C for 5
minutes for 35 cycles with a 72°C extension for 5 minutes. The thermal profile for the
second round PCR was 94°C for 1 minutes, X°C for 2 minutes, 72°C for 3 minutes for 30
cycles with a 72°C extension for 5 minutes. The specific annealing temperatures for the
second round PCR primers are listed in Table 1. Second round PCR products were gel
purified by electrophoresing using 5X gel loading buffer on a 0.7% agarose gel containing
O. 5µg/ml ethidium bromide at 40 Volts, excising the fragment, and isolating the fragment
with Millipore Ultra-free MC filter units using the manufacturer's protocol. PCR
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fragments were quantitated using the ethidium bromide dot method (Sambrook et al.,
1989).

Second round PCR primers were labeled by heating lOpmol of primer with 2.5µ1
lOX labeling buffer in a 25µ1 reaction volume at 70°C for 10 minutes followed by quick
cooling on ice. 10µ1 5X labeling buffer, IOOµCi 32P yATP (6000Ci/mmol, NEN), 0.5M
DTT, and 10 Units PNK were added in a 50µ1 reaction volume and heated at 37°C for 30
minutes. An additional 10 Units of PNK was added and the mixture was heated for an
additional 30 minutes at 37°C. The reaction was heat inactivated at 65°C for 15 minutes.
lOpmol of the opposite (sense or anti-sense) primer was added to its complimentary
labeled primer and the primer pair was cleaned using a Microcon-3 filter (Amicon)
according to the manufacturer's protocol. Second round PCR was performed using the
labeled primer pair and 1µl of the first round PCR product following the above second
round thermal profiles. Radiolabeled PCR products were. gel purified and quantitated as
above.
Heteroduplexes were formed using 100-15011g of normal or mutant product and
1011g of radio labeled normal product with 1Ox annealing buffer in a 3 Oµl reaction volume.
The reaction was boiled for 5 minutes and then heated at 65°C for 1 hour. The reaction
was precipitated by adding 100% ethanol and pelleted by centrifuging at 14,000 rpm for
30 minutes in a micro-centrifuge. The heteroduplexes were dried and resuspended in
13µ1 sterile, deionized water. One half of the heteroduplex was treated with
hydroxylamine and the other half with osmium tetroxide before piperidine cleavage of both
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reactions. Hydroxylamine cleavage was performed by adding 20µ1 of hydroxylamine
solution, pH 6.0 to 6µ1 of the heteroduplex and incubating at 37°C for 30 minutes.
Osmium tetroxide cleavage was performed by adding 10µ1of2.5X osmium tetroxide
buffer, 8µ14% osmium tetroxide to 6µ1 of the heteroduplex solution and incubating at
37°C for 20 minutes with mixing every 2-3 minutes. The reactions were stopped by
adding I 00µ1 of hot stop buffer and 250µ1 of I 00% ethanol and pelleted by centrifuging at
14,000 rpm for 30 minutes in a micro-centrifuge. The hydroxylamine cleavages were
washed twice with 70% ethanol, centrifuging at 14,000 rpm for 2 minutes after each wash
and the osmium tetroxide cleavages were washed once with 70% ethanol, centrifuging at
14,000 rpm for 2 minutes. The products of both reactions were dried in a Savant Speed
Vac and cleaved with piperidine by adding 50µ1 of IM piperidene, vortexing briefly, and
incubating at 90°C for 30 minutes followed by cooling to 0°C. The piperidine cleavages
were carried out in a Biometra TRIO-thermoblock thermal cycler. The cleavages were
terminated by adding 3M sodium acetate, pH 5.2 containing l.6mg/ml tRNA and 100%
ethanol and pelleted by centrifuging at 14,000 rpm for 30 minutes in a micro-centrifuge.
The cleavage products are washed once with 70% ethanol, centrifuging at 14, 000 rpm for
2 minutes. The cleavage products were dried in a Savant Speed Vac and resuspended in
10µ1 of formamide loading dye (Stop Solution, USB). The cleavage products were
vortexed for I 0 seconds to resuspend and heated to 95°C for 3 minutes before they were
electrophoresed on a IX TBE 15% polyacrylamide gel at 75 Watts. 2.5µ1 of the cleavage
products were loaded onto the gel and run for I hour. At this point another 2.5µ1 of the
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cleavage products were loaded onto the gel and run until the bromophenol blue dye front
reached the bottom of the gel. The two different running times were used to give better
resolution of both ends of the cleaved fragment.
Radiolabeled molecular weight markers pBR 322/Msp I (NEB)and <l>X 114/Hae
Ill (NEB) were loaded onto the gel with the samples. Markers were radiolabeled by end-

labeling by adding 2.5µ1 of 5X exchange buffer (BRL), 50µCi ofy 32P ATP
(6000Ci/mmol, NEN), and lOUnits polynucleotide kinase (BRL) to 250ytg of either
marker in a reaction volume of 25µ1 and incubating at 37°C for 30 minutes and 75°C for I
minute to inactivate the PNK. Dilutions of the radio labeled markers were made and
loaded onto the gel according to the specific activity required. The gel was then dried and
exposed to autoradiography film at -80°C.

NIRCA. Mutation analysis was also performed by NIRCA (Ambion Inc.) following the
manufacturer's protocol. First round PCR products from CMC were used and second
round PCR was performed using primers listed on Table 2. Oligonucleotide primers were
designed using Oligo 5. 0 Primer Analysis Software (NBI). PCR was performed in 25 µl
reaction volume using 0.5µ1 of first round PCR product as a template with 2.5U Taq DNA
polymerase (BRL), 10µ1 of IOX PCR buffer (BRL), 4µ1 50mM MgCh, 16µ1 IOmM
mixed dNTP stock, and I OOµM final concentration of PC~ primers unless otherwise
indicated. The thermal profile for the second round PCR was 94°C for 25 seconds, X°C
for 20 seconds, 72°C for 40 seconds for 30 cycles with a 72°C extension for 5 minutes.

15

The specific annealing temperatures for the second round PCR primers are listed in Table
2. Gels were run using a 5µg per lane of a 100 bp marker (Promega) that was diluted in
the NIRCA RNase digestion buffer and gel loading buffer.

Sequencing. Areas suspected to have a mutation after chemical mismatch cleavage
analysis were PCR amplified from a larger PCR fragment using either a forward or reverse
CMC second round primers that were biotinylated. See Table 1 for primer and cycle
profile. The primers were biotinylated using the Oligonucleotide Biotin Labeling kit
(NEB). 750 pmol of primer was biotin labeled following the manufacturer's protocol.
The biotinylated primers were purified ProbeQuant Columns (Pharmacia) following the
manufacturer's protocol. The concentration of the biotinylated primers were determined
using a UV spectraphotometer. PCR was performed using one biotinylated primer and the
complimentary non-biotinylated primer. These reactions were identical to the above nonbiotinylated PCR except that the biotinylated primer had a final concentration of SOµM
and the non-biotinylated primer had a final concentration of 1OOµM. The biotinylated
strands were separated from the non-biotinylated strands for sequencing using M-280
streptavidan magnetic beads (Dynal, Inc.) following the manufacturer's protocol except
that 90µ1 of PCR product instead of 40µ1 PCR product as the Dynal protocol suggests.
All solution amounts in the manufacturer's protocol were scaled up for the use of 90µ1 of
PCR product. The biotinylated strand, attached to the M-280 streptavidin beads, was
resuspended in 7µ1 of sterile, deionized water prior to sequencing. The non-biotinylated
strand was precipitated following the manufacturer's protocol, resuspended in 7µ1 of
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sterile, deionized water. The biotinylated strand was sequenced while remaining attached
to the streptavidin beads. Biotinylated and non-biotinylated strands were sequenced by
the dideoxy chain termination sequencing method (Sanger et al., 1977) using the
Sequenase Version 2.0 kit (NEB) or the Fidelity Sequencing kit (Oncor) following the
manufacturer's protocol. Sequencing primers were designed using Oligo 5. 0 Primer
Analysis Software (NBI). See Table 3 for sequencing primers. The manufacturer's
protocol for Fidelity (Oncor) was not modified. The manufacturer's protocol for
Sequenase (NEB) was modified as follows: 4 pmol of primer was used per sequencing
reaction, the extension reaction was carried out for 2 minutes at 20°C, and the termination
reaction was carried out for 10 minutes at 50°C. The biotinylated strand sequencing
reactions were then separated from excess primer and reaction components using a Dynal
magnet, resuspended in 6 µl of sterile, deionized water and 4 µl Stop Solution (USB), and
heated to 95°C to remove the reaction from the magnetic beads prior to loading the
reactions onto a polyacrylamide gel. The non-biotinylated strand sequencing reactions
were heated to 75°C for 2 minutes prior to loading onto the polyacrylamide gel. 2.5 µl of
each reaction were loaded onto a 5% Long Ranger (J.T. Baker)/0.6X TBE polyacrylamide
gel and run at 85 Watts for 1-3 hours as needed for the particular mutation. The
sequence was dried and exposed to autoradiography film at room temperature.

ASO Analysis. Single base pair mutations that were located by sequencing were
confirmed by ASO analysis. PCR was performed on 25011g of genomic DNA using
primers listed on Table 5. PCR primers were designed using Oligo 5.0 Primer Analysis
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Software (NIB). The PCR was performed in 50µ1 reactiQns with 2.5U Taq DNA
polymerase (BRL), 15.5µ1 of gelatin PCR buffer (Rigat et al., 1992), 10µ1 lOmM mixed
dNTP stock, and lOOµM final concentration of PCR primers unless otherwise indicated.
The thermal profile for the second round PCR was 94°C for 1 minute, X°C for 2 minutes,
72°C for 3 minutes for 40 cycles with a 72°C extension for 5 minutes. The specific
annealing temperatures for the PCR primers are listed in Table 4. 10µ1 of PCR product
was combined with 40µ1 of sterile, deionized water, 2µ1 ION NaOH, and lµl 0.5M EDTA
and heated to 100° C for 10 minutes. The mixture was blotted onto a pre-wetted,
positively charged nylon membrane (Boehringer Mannheim) using a Dot Blotting
apparatus (BioRad) following the manufacturer's protoc~l. The blot was baked at 80°C in
a vacuum oven for 2 hours to fix the DNA to the nylon. To check the amounts of cDNA
bound to the membrane, the blots were stained with a 0.02% methylene blue solution for
10 minutes and de-stained with deionized water three times for 15 minutes each. The
blots were then hybridized with a end-labeled ASO. See Table 5 for ASO probes used.
The radiolabeled ASO probe was added to the blot in 5 mis of Zeta probe hybridization
solution and hybridized overnight at 42°C. The blot was rinsed once with 6X SSC/0.1 %
SDS at room temperature, washed twice with 6X SSC/0.1 % SDS at room temperature,
and washed twice with 6X SSC/0.1 % SDS at X°C. See Table 6 for wash temperatures
for specific ASO probes). The blot was wrapped in saran wrap and exposed to
autoradiography film at -80°C.
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Results

Mutation Analysis
CMC Analysis. FBN2 was analyzed as seven overlapping fragments of approximately
1. 5 kb for CMC analysis due to the size constraint of 1. 7 kb of the CMC system. MF AP3 was analyzed by CMC as one piece due to its smaller size fitting the size constraints of
the CMC system. Only one member of each family was analyzed in cases where multiple
family members were available. Both the sense and anti-sense strands of the patient's
cDNA were analyzed to insure that no mutations were missed. CMC gels were scored as
a positive result on the basis of autoradiography bands appearing in the patient lanes which
did not appear in the control lane. Positives could appear as a band in either a
hydroxylamine or an osmium tetroxide lane. A band in a hydroxylamine lane indicated a
cytosine mismatch and a band in an osmium tetroxide lane indicated a thymine mismatch.
Positives appeared at a distance from either the 5' or 3' end of the fragment depending on
the cDNA strand. For example, a positive signal on the gel in the sense strand lane would
indicate that the mutation was located some certain distance from the 5' end of the
fragment. The positives could be assigned a localized area in the gene based on their
distance from the end of their specific fragment.
Four positives were found for the FBN2 gene. All positives were found in the
hydroxylamine lanes. Positives for FNB2 were found at 350 hp from the 5' end of the first
fragment for patient 4-1-1, 650 hp from the 5' end of the second fragment for patient 1-11, 315 hp from the 3' end of the second fragment for patient 3-1-1, and 350 hp from the 5'
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end of fragment six for patients l-I-1, 2-I-l, 3-I-l, and 4-I-l. These positives were
localized to the areas encompassing nucleotides 485 for patient 4-I-l, 2010 for patient I-II, 2545 for patient 3-I-l, and 7180 for patients l-I-1, 2-I-l, 3-I-l, and 4-I-l (Figure 3).

NIRCA Analysis. FBN2 and MF AP-3 were analyzed as overlapping fragments of 700-

800 bp for NIRCA analysis. NIRCA analysis was scored as a positive if a band or
multiple bands were present on the agarose gel in the patient sample lanes that were not
present in the control lane. Both the sense and anti-sense strands of the patient's
transcribed RNA were analyzed to ensure that no mutations were missed. NIRCA
analysis will give a localization of the mutation from either the 5' or 3' end of the
fragment. NIRCA analysis will not however indicate whether the mutation is a particular
distance from the 5' or 3' end of the fragment. Further NIRCA analysis is necessary to
localize the exact mutation location relative to the 5' or 3' end of the fragment. NIRCA
analysis was performed on a region of FBN2 that contained a known polymorphism. The
normal control was known to be homozygous for the polymorphism, patient I-II- I was a
known heterozygote, and patient 1-I- l was known to be homozygous for the wild-type.
Patient 1-I- l was used as the heteroduplex control. The duplex of 1-I- l : 1-I-1 showed no
bands, the duplex 1-I-l:normal control showed two intense bands at 350 bp and 500 bp,
and the duplex l-I-1:1-II-l showed two less intense bands at 350 bp and 500 bp (Figure
4). These bands would indicate a mutation that was causing RNase cleavage 350 bp from
either the 5' or 3' end of the fragment. Results from the NIRCA analysis of the remainder
ofFBN2 and MFAP-3 are pending.
20

Sequencing. Sequencing was carried out as described in the Materials and Methods
section using primers listed on Table 3. Initial sequencing was carried out using
Sequenase v2.0 (USB) and repeat sequencing was carried out with the Fidelity
Sequencing system (Oncor).
FBN2, nucleotide 485. Sequencing of the area encompassing the mutation at
nucleotide 485 in patient 4-1-1 revealed two transitions at nucleotides 486 and 487 (Figure
5). Both transitions were located in exon 4 ofFBN2 and were cytosine to thymine
substitutions. The first transition at nucleotide 486 would result in a silent polymorphism
with no amino acid substitution. The second transition at nucleotide 487 would result in
the substitution of a tyrosine for the expected histidine. Repeat sequencing after ASO
analysis revealed these transitions to be a partial compression band and not point
mutations.
FBN2, nucleotide 2010. Sequencing of the area encompassing the mutation at
nucleotide 2010 in patient 1-1-1 revealed two transversions at nucleotides 2026 and 2030.
Both transversions were located in exon 15 ofFBN2 and were guanine to cytosine
substitutions. The first transversion at nucleotide 2026 would result in a glutamine
substituted for the expected glutamic acid. The second transversion at nucleotide 203 O
would result in an alanine substituted for the expected glycine. The first transversion
would be more detrimental that the second as the first is ci change from an acidic amino
acid to a neutral amino acid while the second is an exchange of two neutral amino acids.
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Repeat sequencing revealed these transversions to be sequence artifact and not point
mutations.

FBN2, nucleotide 2545. The sequencing of the area encompassing the mutation
at nucleotide 2545 revealed no point mutations. It did ho.wever reveal a compression band
in the patient sample which was not present in the control sample. Compression bands can
be detected as mismatches by CMC. This mutation possibility was discarded from further
analysis.

FBN2, nucleotide 7180. The sequencing of the area encompassing the mutation at
nucleotide 7180 revealed a transition at nucleotide 7197 (Figure 6). The transition at this
position was located in exon 57 ofFBN2 and resulted in a thymine to cytosine substitution
which results in a silent polymorphism with no amino acid substitution. Further
sequencing of patients 1-11-1 and 1-11-2 confirmed this polymorphism. Patients 1-1-1, 111-2, and 4-1-1 were homozygous for the wild-type sequence. Patients 1-11-1 and 2-1-1
were heterozygous. Patient 3-1-1 and the normal control were homozygous for the
polymorphism. Patients 2-1-2 and 5-1-1 were not sequenced for this area.

ASO Analysis. ASO analysis was performed as detailed in the Materials and Methods
section using PCR primers listed on Table 4 and oligonucleotide probes listed on Table 5.
Assigning positive signals was based on the presence of a signal dot on the radiography
film based on the amount of the sample loaded. Positives could be intense indicating the
sequence probed for was present on both alleles or faint indicating the sequence probed
for was present on only one allele. Negatives were assigned where there was no signal on
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the radiography film in the area of a patient or control sample. Loading of the samples
was assessed by Methylene blue staining of the dot blot prior to hybridization with
oligonucliotide probes.

FBN2, Exon 4. ASO analysis was carried out on patient 4-1-1 and 50 normal
controls. All samples produced a visible signal of approximately equal intensity based on
their loading for the normal oligonucleotide probe. None of the samples, including the
patient sample, produced a visible signal for either the polymorphic probe, the mutant
probe, or the combined polymorphic/mutant probe.

FBN2, Exon 15. ASO analysis was carried out for patients 1-1-1, 1-11-1, 1-11-2
and 50 normal controls. All samples produced a visible signal of approximately equal
intensity based on their loading for the normal oligonucleotide probe. None of the
samples, including the patient sample, produced a visible signal for either the polymorphic
probe, the mutant probe, or the combined polymorphic/mutant probe.
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Discussion

Mutation Analysis
CMC Analysis. The positive CMC result for FBN2 in the area of nucleotide 7180 was
the first positive found in the CMC analysis of either FBN2 or MF AP3. It was suspected
that any change in this area was the result of a polymorphism rather than a disease
associated mutation because evidence from the mutation analysis ofFBN2 (Putnam et al.,
1995) has not shown a universal mutation for aU CCA patients. It is more probable that a
commonly occurring polymorphism would be present in either one copy or both for the
majority of the patients analyzed. The positive signal for patient 1-1-1 was more intense
than the signal for the other three patients. After sequencing revealed the change in the
sequence to be a polymorphism at nucleotide 7197 occurring in the normal control and
five of the patients, it was noted that the intensity of the CMC signal could correspond to
the sequence change occurring as a heterozygote or homozygote. When patient 1-1-1, a
homozygous wild-type individual, was hybridized with the normal control, a homozygote
for the polymorphism, the CMC signal was very intense. On the contrary, when patient 4I-1, a heterozygote for the polymorphism, was duplexed with the control, a less intense
but still positive result was seen. These results would indicate that CMC is a sensitive
enough technique to detect a heterozygous mutation. The heteroduplex between patient
2-1-1 and the control would also have been expected to be very intense which is not the
case as seen in Figure 3. This sample proved to be extremely difficult to analyze for all of
the fragments ofFBN2 and, therefore, less of this sample was loaded onto the CMC gels
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with respect to the other samples. The reason for the difficulty in analysis of this patient
may be related to the poor quality of the fibroblast cells, which did not grow as well as
expected. The RNA and DNA isolations were difficult for this sample and the purity of
the RNA and DNA with respect to proteins and cellular debris was questionable.
The polymorphism at nucleotide 7197 became a valuable resource, as it was used
to optimize the conditions of the CMC technique. A review of the CMC literature
published to date shows that the incubation times of the modification of the
heteroduplexes with hydroxylamine and osmium tetroxide to be arbitrary. If the chemical
modifiers are incubated with the heteroduplex for too long of a time period aberrant
nonspecific bands could occur in hyper-sensitive regions of the sequence. These aberrant
bands could be mistaken for actual mismatches, wasting valuable time and resources in
sequencing areas containing no mutations. Conversely, if the incubation with the
modifying chemicals is too short, actual mismatches may be missed because they were not
modified. By using heteroduplexes with known mismatches based on the polymorphism
at nucleotide 7197, we were able to vary the chemical modification incubation times until
we obtained a result that indicated to us the optimal incubation time that would minimize
aberrant bands and maximize actual mismatches in the sequence. Once these optimal
incubation times were discerned, the rest of the FBN2 gene and the MFAP-3 gene were
analyzed by CMC.
It has been noted that compression artifacts can cause false-positives in CMC
analysis (Cotton et al., 1988; Grompe et al.,

1989~

Mathew, 1991). The positive CMC

results for FBN2 in the areas of nucleotides 485, 2010, and 2545 were found to be the
25

results of compression bands causing a false-positive signal. The false-positive result is
thought to be the result of modification of the compressed area by virtue of its secondary
structure. The chemical modification of the area could be an over-modification and would
result in the area being sensitive to cleavage by piperidine. Once a compression is found in
the area of a positive CMC signal, it is usually useless to look for any other sequence
changes. Therefore, we were not surprised to discover that the area encompassing these
three CMC positives contained no mutations.

NIRCA Analysis. NIRCA was performed on the region ofFBN2 containing the
polymorphism at nucleotide 7197 to test the accuracy of the assay and also to optimize the
assay conditions. We needed to know if NIRCA could detect a heterozygote easily and
reliably without giving an obscure or difficult to interpret result. The results ofNIRCA
analysis were positive. NIRCA analysis was able to detect a homozygous mismatch
(Figure 4, lanes 1 and 4) at a higher intensity that a heterozygous mismatch (Figure 4,
lanes 2 and 5) but the heterozygote detection was still very clear. Three different
dilutions of the three RNase stock solutions were used on the polymorphic
heteroduplexes: the standard dilution suggested by the manufacturer, a dilution twice that
of the standard, and a dilution one-half that of the standard. No discernible differences
were noted between the three dilutions. The higher dilution did not result in an increase in
aberrant bands and the lower dilution was still able to detect the mismatch although not as
intensely as the standard dilution. The remaining fragments of the FBN2 gene and the
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MF AP3 gene are being analyzed presently using the standard dilution of the RNase stocks
and no data is available for them.

Sequencing. PCR products are difficult to sequence because it is difficult to maintain
single strands which are necessary for sequencing. PCR products can be denatured but
will readily reanneal making it nearly impossible to anneal the sequencing primer to the
strand of interest to continue the sequencing procedure. This difficulty was overcome by
biotinylating one of the PCR primers used to generate the DNA fragment to be sequenced.
The biotinylated strand of the PCR product can then be separated from the nonbiotinylated strand by magnetic separation using streptavidin coated magnetic beads
utilizing the interaction between streptavidin and biotin. Using this procedure the PCR
product was separated into single strands that could be sequenced by dideoxy-chain
termination sequencing.
Compression bands, partial compression bands, and sequence artifacts which are
aberrant bands appearing on the sequencing gel are common problems with sequencing
DNA. PCR products add another level of difficulty by introducing amplified sequence
that may not be complete at the 5' and 3' ends or may have errors in the sequence that
have been introduced by the PCR procedure itself The difficulties of sequencing PCR
products that may have incomplete 5' and 3' ends can be overcome by the use of
sequencing primers that lie within the PCR fragment and do not overlap with the PCR
primers or by using "nested" PCR primers that lie within the area of the first PCR primers.
The "nested" PCR primers are used in a second round of PCR. The difficulties that arise
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from PCR artifact are not as easily solved. These artifacts can be present in either the
normal control or the patient sample. Repeating the PCR and the sequencing reactions
will usually yield the correct sequence because it is unlikely that a random PCR error
would be introduced on two separate occasions. Compression bands cause areas of the
DNA sequence that are not separated into single base pairs during sequencing.
Compressions result in a solid line that is present in all four lanes of the sequencing gel at
one time. They can be present for a single base pair or for several bases in a series.

Partial compressions are compression bands seen in two or three lanes at one time but not
all of the lanes as a normal compression. Compressions and partial compressions must be
dealt with by either changing the sequencing conditions or the sequencing system that is
being used. Different sequencing systems make use of different enzymes to carry out the
sequencing procedure and these enzymes will react with different aberrations of the DNA
in different ways. Some enzymes and temperature conditions will sequence through a
difficult area with little or no trouble where others may result in partial or full
compressions.
One indication of sequence artifact or partial compression bands is the presence of
more that one transition or transversion occurring in succession or relatively near another.
Initial sequencing with the Sequenase v2.0 kit (USB) for FBN2 in the regions of
nucleotides 485 and 2010 both had two sequence alterations within a few base pairs of
each other. The sequences would indicate that the regions contained a mutation and a
polymorphism in the same area which is not impossible but is unlikely. When ASO
analysis revealed that there were no changes to the sequence in these areas, the fragments
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were sequenced with the Fidelity Sequencing kit (Oncor). The Fidelity kit was used
because it uses T4 DNA polymerase instead ofT7 DNA polymerase used by Sequenase
v2. 0 and higher temperatures. The Fidelity kit was able to sequence through the partial
compressions to reveal normal sequence. These areas were discounted as areas of
mutation in FBN2. The secondary sequencing of these areas proves that the ASO analysis
was working properly to detect single base changes in the sequence. ASO analysis is still
considered to be a reliable method of mutation

confirmati~n.

Initial sequencing with the

Sequenase v2.0 kit (USB) for FBN2 in the region of nucleotide 2545 revealed no point
mutations and a compression band. The compression was in the correct area to allow for
a CMC positive signal so the area was also discounted as an area of mutation in FBN2.

Conclusions. To date, this study has not revealed any mutations in the FBN2 or MF AP-3
genes that are associated with CCA. It did, however, reveal one polymorphism that was
used to optimize the NIRCA system. As no mutations have been found in families
affected with CCA, an inheritance pattern demonstrating co segregation of the CCA
phenotype with a FBN2 or MF AP-3 mutations cannot be established. FBN2 and MF AP-3
cannot be discounted as the gene or genes associated with CCA. CMC has not been
shown to be an effective mutation analysis system for either of these genes. This could be
a result of the high G-C to A-T content of FBN2. The G-C to A-T content ofMFAP-3
has not been calculated and could be a factor in mutation analysis. FBN2 has been
difficult to analyze by SSCP and has now been seen to be resistant to CMC analysis.
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NIRCA analysis appears to be useful for mutation analysis ofFNB2 and is currently being
used for that purpose (Note added in proof: see Appendix I).
Sequencing of PCR products is a difficult task which can been made appreciably
easier by the use of biotin labeled primers and streptavidin beads. When used with internal
sequencing primers and a reliable sequencing method, the sequencing of PCR products
becomes a relatively easy task. This biotin-PCR sequencing technique has become an
important technique in this study and other studies we have conducted in other areas.
ASO analysis is a proven technique for mutation confirmation and holds great promise for
use with FNB2 when mutations are located as a rapid mutation detection technique.
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Abstract submitted to the 4th International Symposium on the Marfan Syndrome, Davos,
Switzerland, August 11-14, 1996. The abstract refers to patients 2-1-1and2-1-2.
Aberrant splicing of fibrillin-2 in a family with Congenital Contractural
Arachnodactyly

Cheryl L. Maslen*, Darcie Babcock*, Michael Raghunath#,
Beat Steinmannt
*Oregon Health Sciences University, Portland, Oregon, USA; #University of Munster,
Munster, Germany; tuniversity Childrens Hospital, Zurich, Switzerland.
Congenital Contractural Arachnodactyly (CCA) is an autosomal dominant disorder that is
phenotypically similar to, but genetically distinct from Marfan syndrome. Genetic linkage
analysis implicated the fibrillin-2 gene (FBN2) as the CCA locus. Mutation analysis of
single CCA patients indicate that defects in FBN2 may be responsible for that disorder.
However, co-segregation of a mutant allele with the disease phenotype has not been
established. We have investigated the primary cause of CCA in a large, well characterized
kindred with four documented generations of affected individuals. Previous studies
showed linkage of the CCA phenotype to FBN2. Mutation analysis of the proband's
cDNA using Non-Isotopic Rnase Cleavage Assay (NIRCA, Ambion Corp., Austin Texas,
USA) identified the presence of a skipped exon that was subsequently identified as exon
31. DNA sequence analysis of genomic DNA identified the splice site alteration
responsible for the exon-skipping event. The occurrence of exon skipping was confirmed
in the cDNA of an affected sibling. Genomic DNA from 29 additional available family
members, both affected and unaffected, was then analyzed for the splice site mutation. The
results clearly demonstrate co-segregation of the abberant splice site with the CCA
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phenotype. This unequivocally establishes, for the first tjme, that mutations in FBN2 are
responsible for the CCA phenotype.
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Abstract submitted to the 4th International Symposium on the Marfan Syndrome, Davos,
Switzerland, August 11-14, 1996. The abstract refers to patients 3-I-1, 3-1-2, 3-1-3, and
3-11-1.

A Single Mutation That Results in an Asp~His Substitution and Partial Exon
Skipping in a Patient with Congenital Contractural Arachnodactyly
Cheryl Maslen*, Darcie Babcock*, Cheryll Gasner# and Uta Francke#
*Oregon Health Sciences University, Portland, Oregon, USA; #Stanford University
Medical Center, Stanford, California, USA.
Recent investigations of the molecular basis of congenital contractural arachnodactyly
(CCA) indicate that mutations in the fibrillin-2 gene (FBN2) cause CCA. In order to
determine the range and nature ofFBN2 mutations associated with CCA, we are
examining cRNA from a series of patients using Non-Isotopic Rnase Cleavage Assay
(NIRCA; Ambion Inc., Austin, Texas, USA.). A NIRCA positive result indicated the
presence of a mutation in cRNA prepared from cultured fibroblasts derived from CCA
patient, FB904. The patient has the classic features of CCA; multiple contractures,
arachnodactyly, and crumpled ears, with no apparent heart or eye manifestations. This
mutation had previously gone undetected when cDNA from this individual was analyzed
by chemical mismatch cleavage analysis, indicating that NIRCA may be a more robust
technique for detecting fibrillin mutations. DNA sequence analysis of the NIRCA positive
region detected a G to C transversion at nucleotide 3340 (G3340C), which predicts the
substitution of histidine for asparagine at amino acid residue 1114. This asparagine
residue acts as a calcium-binding ligand in the 12th calcium-binding pEGF-like domain. In
addition, the G3340C mutation alters the last nucleotide of exon 25; position -1 of the 5'
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donor splice site, which is a highly conserved G (77%). Subsequent RT-PCR and DNA
sequence analyses demonstrate that this missense mutation also acts as a splice site error,
resulting in partial skipping of that exon. Consequently, the complex manifestation of this
genotype may result in two different populations of mutant fibrillin-2 molecules as
components of elastic microfibrils in one individual. However, the phenotype of the
affected individual indicates that if both mutant fibrillin-2 forms are present in the matrix,
they are not appreciably less well tolerated than is a singl~ defective molecule.
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Figure 1. Diagramatic representation of the amino acid sequence of fibrillin-2 indicating the
different domains present. Diagram courtesy of Cheryl Maslen.
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Figure 3. Chemical mismatch cleavage of the area encompassing FBN2 nucleotide
7180. Lane 1 is Control, Lane 2 is Pc;ttient 4-I-l, Lane 3 is Patient l-I-1, Lane 4 is Patient
3-I-1, and Lane 5 is Patient 2-I-1 for hydroxylamine cleavage. The band at ,..,,350 hp
indicates a cytosine mismatch for all patients represented. Size markers located to the left
of sample lanes are <I>X 174/Hae III and pBR 322/Msp I.
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Figure 4. NIRCA analysis of the area of a known FBN2 polymorphism. Side A is an
RNase digestion with one-half of the standard dilution of RNase. Side Bis an RNase
digestion with twice the standard dilution ofRNase. Lanes 1 and 4 are Patient 1-11:Control, Lanes 2 and 5 are Patient 1-1-1: 1-11-1, and Lane 3 is 1-1-1: 1-1-1 and serves as
a positive control. Lanes 1 and 2 are Patient 1-1-1 SP6 transcribed and Lanes 4 and 5 are
Patient 1-1-1 T7 transcribed. Bands present are at 500 hp and 350 hp. No markers are
present.

40

G ATC
. ;r

../c

A
--C-T486
-C-T487
A

\G

T

Figure 5. Sequencing of the area encompassing FBN2 nucleotide 485 for patient 4-1-1.
Nucleotides 486 and 487 indicate cytosine to thymine substitutions. Sequencing was
performed with the Sequenase v2.0 kit (USB).
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Figure 6. Sequencing of the area encompassing FBN2 nucleotide 7180 for Control,
patient 1-1-1, and patient 1-11-1. Nucleotide 7197 indicates thymine to cytosine
substitution, resulting in a silent polymorphism. Sequencing was performed with the
Sequenase v2.0 kit (USB).
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Abbreviations

DEPC:

Diethylpyrocarbonate.

DTT:

Dithiothreitol.

EDTA:

Ethylenediaminetetraacetic acid.

GIT:

Guanidinium isothiocyanate solution.

PBS:

Phosphate buffered saline.

PNK:

Polynucleotide kinase.

rpm:

Revolutions per minute.

SDS:

Sodium dodecyl sulphate.

SSC:

Standard saline citrate.

Tris:

Tris(hydroxymethyl)aminomethane.

UV:

Ultra violet.
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Solutions

DNA and RNA Isolations
BCL (blood cell lysis) buffer:

0.32M sucrose, lOmM Tris-Cl, pH 7.5, 5mM
MgCh, 1% Triton X-100

NL (nuclear lysis) buffer:

75mMNaC1, 24mMEDTA, pH 8.0

Proteinase K/SDS:

NL buffer, 0.2mg/ml proteinase K, 0.9% SDS

TE:

IOmM Tris-Cl, pH 8.0, lmM EDTA, pH 8.0

TE-4:

lOmM Tris-Cl, pH 8.0, O. lmM EDTA, pH 8.0

IX PBS (per liter):

8g NaCl, 0.2g KCl, 1.44g Na2HP04, 0.24g
KH2P04

Digestion buffer:

lOOmMNaCl, lOmm Tris-Cl, pH 8.0, 25mM
EDTA, pH 8.0, 0.5% SDS, O. lmg/ml
proteinase K

GIT:

4M guanidinium isothiocyanate, 20mM sodium
citrate, 0.4% n-lauryl-sarcosine

Cesium chloride:

5.7M cesium chloride, lOOmM EDTA, pH 8.0

cDNA synthesis
Mixed dNTP stock ( 1OmM):

lOmM dGTP, lOmM dATP, lOmM dTTP, lOmM
dCTP

Mutation Analysis
50XTAE:

2M Tris, 50mM EDTA, ph 8.0, 5.7% glacial
acetic acid

1OX Labeling buffer:

200mM Tris-Cl, lOmM spermidine, lmM EDTA,
pH8.0

5X Labeling buffer:

250mM Tris-Cl, 50mM MgCh, 25mM DTT, 25%
glycerol

1OX Annealing buffer:

3M NaCl, 30mM Tris, 35mM MgCh
45

Hydroxylamine solution, pH 6.0:

I. 39g hydroxylamine, 1. 6mls sterile deionized
water, Iml diethylamine

2. 5X Osmium tetroxide buffer:

25mM Tris, pH 7-.7, 4mM EDTA, pH 8.0, 3.75%

pyridine
Hot stop buffer:

0.2M NaCl, lOmM Tris-Cl, pH 7.7, lmM EDTA,
pH 8.0, 5µg/µl tRNA

lOXTBE:

I. IM Tris, I. IM boric acid, 20mM EDTA,
pH8.0

Gel loading buffer:

ImM EDTA, pH 8.0, 25mg Bromophenol Blue,
50% glycerol

ASO Analysis
Zeta Probe(BioRad):

0.22MNa2HP04, pH 7.2, 0.5MNaCl, I4% SDS,
2mM EDTA, pH 8.0, 50% formamide

20X SSC (pH 7.0):

3M NaCl, 0.3M sodium citrate

Gelatin PCR Buffer:

IOOmM MgCh, 30mM Tris-Cl, pH 8.4, I67mM
KCl, 0.33µg/ml gelatin
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TABLE 1
FRAGMENT

CMCPRIMERS
SENSE PRIMER (5'-3')

FBN2 First Round
1
2
3

ACAGGTTCGGTCCGCTACAGC
AGTGGCAATGGCAATGGCTATGG
CTGTTGGCTCAACATCCAGGAC
4
GATGTACAGATGTGGATGAGTGTG
5
GTGTGCATTAACCAGATTGGCAGT
6
TCCTATGAATGCACGTGCCCGAT
GCAATTACGGCTGCTCTAACACG
7
MFAP-3 First Round GGTTCTCTACTCACATCT

ANTI-SENSE PRIMER (5'-3'}

ANNEALING
TEMPERATURE

GCTTACAGATATCTATTGTCTGGTTC
GCCAGGGAACACCTCACACTCAT
CGTCCAGATCAATACACTTGATGC
TGATGCAGTCTGCATTCCGCTG
GATGCACATGAAGGTGCCGATTAG
CGTTGATTTTGCACTCGTAGCATG
TCAGCTGCCTACAGTACCATGAG
CTTCTAAGAAACAGGTTCC

68°C
68°C
68°C
68°C
68°C
68°C
68°C
49.9°C

GTCCAGTGATGATAGGTC
TCTTCACACGTAACACCT
TGATGCCGTTTCCAATC
TATCACCATTGCTGCAC
CTAGATTCACAGTCGTG
TCTGGGGACAGAGCAT
TACCATGAGGACGCAG
TTACAGCTGACAGTTTTC

53.8°C
52.8°C
54.9°C
53.8°C
50.8°C
54.8°C
51.7°C
51.1°C

FBN2 Second Round
1

2
3
4

5
6
7

MFAP-3 Second
Round

GTTCGGTCCGCTACAGC
ACAGGCTTCATCCCCAT
TCAACATCCAGGACAGC
TGGTGCTCATAACTGCG
GCTGTGAATGCCCTACA
CTATGAATGCACGTGCCCGA
GCTACCTCTGTGGCTG
ATGAAGCTACATTGTTGC
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Table 2
NIRCA PRIMERS
FRAGMENT SENSE PRIMER (5'-3')
FBN2
1/1
112

2/1
2/2
3/1
3/2
4/1
4/2
5/1
5/2
6/1
6/2

GATAATACGACTCACTATAGGG
CTCTGAAGGCGGGTTT
GATAATACGACTCACTATAGGG
CCATCCCTGTGAGAT
GATAATACGACTCACTATAGGG
AGGGACAGGCTTCATC
GATAATACGACTCACTATAGGG
CTGTGGGCATGGATGG
GATAATACGACTCACTATAGGG
AGCCACTCTGAAATCT
GATAATACGACTCACTATAGGG
ACATTGACGGATGTGA
GATAATACGACTCACTATAGGG
TGCTCATAACTGCGAC
GATAATACGACTCACTATAGGG
AAACCCCTGTGAGACA
GATAATACGACTCACTATAGGG
CAGTTTCCGCTGTGAA
GATAATACGACTCACTATAGGG
TTCCTGTACTAATACT
GATAATACGACTCACTATAGGG
AAGATCAAAAGATGT
GATAATACGACTCACTATAGGG
AGTTATCAGTGTTCA

ANTI-SENSE PRIMER {5'-3'}

ANNEALING
TEMPERATURE

TCATTTAGGTGACACTATAGGA
TAGCCTGGCATTCATC
TCATTTAGGTGACACTATAGGA
TATCTATTGTCTGGTTC
TCATTTAGGTGACACTATAGGA
CGCACACACACTCCTT
TCATTTAGGTGACACTATAGGA
GGGTGGCACAGCATTC
TCATTTAGGTGACACTATAGGA
AAGCTGCCCTCAGTGT
TCATTTAGGTGACACTAT AGGA
TGCCGTTTCCAATCCA
TCATTTAGGTGACACT AT AGGA
TTGTGATGGGGTTAGG
TCATITAGGTGACACTATAGGA
GATTATCACCATTGCT
TCATTTAGGTGACACTATAGGA
GTATCAAAGCATCTCC
TCATTTAGGTGACACTATAGGA
TTAGATTCTTACACAT
TCATTTAGGTGACACTATAGGA
CACAGAGGAACTGGCA
TCATTTAGGTGACACTATAGGA
CAGAGCATTTTCCTCA

56.2°C
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52.7°C
54.4°C
56.0°C
55.1°C
54. 9°C
54. 7°C
51.9°C
51.6°C
49.1°C
52.7°C
53.9°C

7/1
MFAP-3
1

2

GATAATACGACTCACTATAGGG
TATTACAGAGTGGGA

TCATTTAGGTGACACTATAGGA 53.4°C
GGGTCAACATTCAAAG

GATAATACGACTCACTATAGGG
AAAATATCTCTACCAA
GATAATACGACTCACTATAGGG
CCATCAATGAGTTCT

TCATTTAGGTGACACTATAGGA 50.0°C
GTTTTGGCTGAGGTAA
TCATTTAGGTGACACTATAGGA 52.4°C
GCGAGCTGATTTTGT
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TABLE3
GENE
FBN2

SEQUENCING PRIMERS
PRIMER (5'-3')

DIRECTION

POSITION (bo)

1

GATGGAAGACGCTCCCTGGAG
TGTGTTTGAATGGAATGTGC
CATTCGGACTTGGTCACTGC
GTGCCGAAACACGCCAGGAA
GTCCCCTTCAGGCTGTCAA
CCAGGAATCTGTGAAATGGACTG
ATGAAGCTACATTGTTGC
TTACAGCTGACAGTTTTC

Sense
Sense
Anti-sense
Sense
Anti-sense
Sense
Sense
Anti-sense

299
1874
2180
2472
2687
7033
1
1089

2/A-F
2/A-R
2/B-F
2/B-R
6

MFAP-3/F
MFAP-3/R
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TABLE 4
EXON

PRIMERS FORASO ANALYSIS
SENSE PRIMER (5'-3')

ANTI-SENSE PRIMER (5'-3')

ANNEALING
TEMPERATURE

4

TCAGCAGTGCAGTGTGAG
GATGTTGATGAATGCCAG

TCCACAATATGTTCCAAT
ATCCATGCCCACAGCCAG

49.2°C
53.6°C

15
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TABLES
EXON

ASOPROBES
ASO SEQUENCE

BASE CHANGE

AMINO ACID CHANGE

WASH
TEMPERATURE

4
4
4
4
15
15

CAGATGACCACTGCCA
CAGATGATCACTGCCA
CAGATCATTACTGCCA
CAGATGACTACTGCCA
ACAGTGAAGGGTCCT
ACAGTCAAGCGTCCT

No Change
486 hp
486/487 hp
487 hp
No Change
2026/203 0 bp

50°C
48°C
46°C
48°C
46°C
46°C

15
15

CAACAGTCAAGGGTC
AGTGAAGCGTCCTTC

2026 bp
2030 bp

No Change
No Change
No Change/Histidine-Tyrosine
Histidine-Tyrosine
No Change
Glutamic Acid-Glutamine/
Glycine-Alanine
Glutamic Acid-Glutamine
Glycine-Alanine
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46°C
46°C
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